Vaxinia has shown plenty of successful tests in animals and the true test for its authenticity would be its effectiveness in humans. The next step has been taken as scientists have injected the first human patient with the new cancer-killing virus.

The Right Route: The Site of Injection Matters | Emergency Physicians Monthly — **Image Source**

Whenever people hear of a virus, they think of something bad. They aren’t to blame. I mean, we did just go through a pandemic caused by the Covid virus. However, the goal is that the virus used will amplify the body’s immune response against whatever cancer an individual has. The virus has also been engineered to kill cancer cells - nothing else.

Success with these forms of studies has been limited. The difference with Vaxinia is that it doesn’t only kill cancer, but it also magnifies the cancer cells for the immune system.

In many of the animal testing trials, scientists witnessed huge success. Specifically in terms of shrinking tumors within the lungs, breasts, ovaries, pancreas, and the colon. With this amount of success, it has been decided to move on to the next big thing: Human Testing.

This is just Phase 1 of just 100 cancer patients having metastatic or advanced solid tumors with each patient having tried two or more treatments. Being split into two different groups, one group will receive ONLY Vaxinia and the other will receive Vaxinia and an immunotherapy drug. This phase of trials is typically used to learn more about the safety of the drug as well as discover the needed dose. The competition is expected to be in early 2025 so it will be a little bit longer to see the final results but nevertheless, this is huge news for cancer and the medical community.

Uniic Media

Cancer-Killing Virus begins Human Trials